EG&G/Wallac
This article was originally published in The Gray Sheet
Executive Summary
Two firms sign a definitive agreement for EG&G to acquire Wallac, a unit of Procordia AB, for approximately $46 mil. Headquartered in Finland and with employees in Scandinavia, the U.K. and the U.S., Wallac posted roughly $50 mil. in 1992 sales. The producer of analytical and diagnostic systems, instruments and reagents will report to EG&G's instruments division, which markets medical, environmental and analytic monitoring products and accounts for approximately $227 mil. of EG&G's $2.7 bil. in annual revenues.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.